Fulcrum Therapeutics, Inc. — Form D/A
Fulcrum Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D amendment with the SEC on 2017-07-25. The offering totals $55.0M, of which $29.7M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-07-25
- Form: D/A
- Accession: 0001680581-17-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $55.0M
- Amount sold: $29.7M
- Remaining: $25.3M
- Investors: 1
- Date of first sale: 2016-07-18
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-267612
Issuer
- Name: Fulcrum Therapeutics, Inc.
- CIK: 0001680581
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
- Phone: 617-651-8851
Officers, directors & promoters (13)
| Name | Role | Location |
|---|
| Alan Ezekowitz | Director | WATERTOWN, MA |
| James Collins | Director | Cambridge, MA |
| James Tananbaum | Director | South San Francisco, CA |
| Mark Levin | Director | New York, NY |
| Robert Gould | Director | Portland, ME |
| Robert Gould | Executive Officer | Portland, ME |
| James Geraghty | Director | Cambridge, MA |
| Diego Cadavid | Executive Officer | Cambridge, MA |
| Kate Haviland | Director | Cambridge, MA |
| Katina Dorton | Director | Cambridge, MA |
| Bryan Stuart | Executive Officer | Cambridge, MA |
| Owen Wallace | Executive Officer | Cambridge, MA |
| Amit Hasija | Executive Officer | Cambridge, MA |
Other filings by this issuer (4)
More